In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chattem

This article was originally published in The Rose Sheet

Executive Summary

Net sales are expected to fall approximately 4%-6.5% to $78 mil.-$80 mil. from $84.3 mil. for the fiscal second quarter (ended May 31), the company reports. EBITDA for the period should range from $21 mil.-$22 mil., versus $26.3 mil. in the same period last year. The forecasted decline is attributed to continued weakness in Sunsource dietary supplements and increased competition against Ban antiperspirants, namely Unilever's Dove product. Radio and TV ads featuring Chattem's new Ban Naturals will break in mid-July and run throughout the year. The company also will drop FSIs from July-September. Chattem has earmarked $20 mil.-$30 mil. for Ban this year (1"The Rose Sheet" Jan. 31, p. 6)

You may also be interested in...



Chattem

Net sales declined 4.6% to $79.6 mil. for the second fiscal quarter (ended May 31), while earnings rose 6% to $6.1 mil. For the half, sales slid 2.8% to $142 mil., and earnings rose 2.9% to $9.2 mil. Results were impacted by low sales of Ban antiperspirant. Chattem has earmarked its entire Ban ad spend for the Ban Naturals second half launch and thus aired no ads in the first half. The company also attributed the sales downturn to the poor performance of Sunsource dietary supplements. Chattem earlier had predicted overall sales would fall 4%-6.5% (1"The Rose Sheet" June 19, In Brief). Sales for the remaining brands rose 4.1% for the quarter and 5.5% for the half. Upcoming introductions include Gold Bond Fragrance Free Lotion, which will bow in fiscal third quarter with marketing support in the fourth

Chattem

Net sales declined 4.6% to $79.6 mil. for the second fiscal quarter (ended May 31), while earnings rose 6% to $6.1 mil. For the half, sales slid 2.8% to $142 mil., and earnings rose 2.9% to $9.2 mil. Results were impacted by low sales of Ban antiperspirant. Chattem has earmarked its entire Ban ad spend for the Ban Naturals second half launch and thus aired no ads in the first half. The company also attributed the sales downturn to the poor performance of Sunsource dietary supplements. Chattem earlier had predicted overall sales would fall 4%-6.5% (1"The Rose Sheet" June 19, In Brief). Sales for the remaining brands rose 4.1% for the quarter and 5.5% for the half. Upcoming introductions include Gold Bond Fragrance Free Lotion, which will bow in fiscal third quarter with marketing support in the fourth

Chattem Ban $30 Mil. Ad Spend Includes Natural Antip/Deo Launch

Chattem will back its Ban antiperspirant/deodorant brand with a $20 mil.-$30 mil. advertising spend in 2000, the firm announced during a conference call Jan. 25. A significant portion of the budget will be dedicated to the April 15 launch of Ban Natural.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS008114

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel